HIBISCUS-STEMI Biobank: High quality samples for powerful research on STEMI biomarkers

Abstract

The HIBISCUS-STEMI BIOBANK (coHort of patients to Identify Biological and Imaging markerS of CardiovascUlar outcomes in ST elevation myocardial infarction) is based on a prospective cohort of 500 patients with ST elevation myocardial infarction (STEMI), supported by the RHU MARVELOUS (ANR-16-RHUS-0009). Its primary objective is to identify new biomarkers of clinical outcomes with specific attention to heart failure. All patients with suspicion of STEMI have given written consent and clinical, laboratory and imaging information has been recorded in the database of the Lyon Clinical Investigation Center (CIC). Blood sampling (taken 24/7) (24 mL) was repeated 5 times: before PCI (Percutaneous Coronary Intervention), at 4-24-48 hours and 1 month after PCI. Blood was immediately transferred to the local biobank to be processed in serum, plasma or peripheral blood mononuclear cells (PBMC), and cryopreserved at −80 °C or in liquid nitrogen. Total blood was also stored for future genetic studies. The biobank has been certified for NF S96-900 French norm and assure traceability and quality of samples and storage. More than 36,000 high quality biological samples associated with clinical and MRI (magnetic resonance imaging) data are already available and several projects are ongoing with new biomarkers being identified, e.g. to explore the role of inflammation in myocardial ischemia-reperfusion damage and development of LV remodeling and heart failure within 1 year after AMI. The HIBISCUS-STEMI Biobank is a powerful tool for biomarkers research, available for academic or industrial collaboration. This will help to better understand the mechanisms of AMI and, to improve our assessment of individual prognosis after acute myocardial infarction.